Featured Research

from universities, journals, and other organizations

Regorafenib: hint of minor added benefit

Date:
January 10, 2014
Source:
Institute for Quality and Efficiency in Health Care
Summary:
Patients with metastatic colorectal cancer have severe side effects more frequently under treatment with regorafenib, but they survive longer.

Regorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an option. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

Related Articles


According to the findings, there is a hint of a minor added benefit of regorafenib. Patients have a survival advantage, but certain severe side effects occur more frequently.

"Best supportive care" was appropriate comparator therapy

The G-BA specified "best supportive care" (BSC) as appropriate comparator therapy. BSC means a therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms and improve quality of life.

The manufacturer presented data from the approval study (CORRECT) in its dossier. One study group was treated with regorafenib plus BSC, and the control group received a placebo plus BSC. However, it was not allowed to use other systemic anticancer treatments as part of the BSC.

Reduced reliability of the conclusions: not more than a hint can be derived

There are several reasons why the reliability of the conclusions of the results from CORRECT is limited: On the one hand, it remained unclear whether the excluded anticancer treatments would have been able to relieve the symptoms and thus should have been part of the -- palliative -- BSC. In the follow-up phase, i.e. after the end of the study treatment, 25 to 30 per cent of the patients received this kind of further systemic anticancer treatment.

On the other hand, only patients with a certain status of the disease (ECOG-PS 0 or 1) could participate in the study, although regorafenib is also approved for patients with poorer general condition (ECOG-PS > 1).

For these reasons, not more than a hint of an added benefit can be derived from the data presented in the dossier.

Advantage in overall survival

The analysis of the data showed a statistically significant difference between the two study arms in favor of regorafenib for the outcome "overall survival." Half of the patients who received regorafenib had died after 6.5 months. In the control group, this was already the case after about 5 months. IQWiG therefore considers there to be a hint of a considerable added benefit.

Data on morbidity and quality of life were not evaluable

Data on symptoms and complaints (morbidity) and on health-related quality of life were recorded with questionnaires, but were not evaluable for the benefit assessment. The main reason was that this information was only actually available for some of the participants at the end of the treatment (< 70%). The low response rate of the questionnaires cannot be sufficiently explained by the death of these patients.

Severe side effects more frequent under regorafenib

There were no statistically significant differences between the two treatment arms with regards to serious adverse events and treatment discontinuation due to adverse events. The situation was different with regards to severe side effects (CTCAE Grade 3): They were more frequent in the regorafenib group than in the placebo group. The biggest differences (? 5%) occurred in fatigue, diarrhea, hand-foot syndrome and certain types of skin rash (exanthemas).

Regarding side effects, IQWiG therefore derives a hint of greater harm with the extent "major." However, this greater harm does not completely outweigh the survival advantage, so that, overall, IQWiG considers there to be a hint of a minor added benefit.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Regorafenib: hint of minor added benefit." ScienceDaily. ScienceDaily, 10 January 2014. <www.sciencedaily.com/releases/2014/01/140110103522.htm>.
Institute for Quality and Efficiency in Health Care. (2014, January 10). Regorafenib: hint of minor added benefit. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2014/01/140110103522.htm
Institute for Quality and Efficiency in Health Care. "Regorafenib: hint of minor added benefit." ScienceDaily. www.sciencedaily.com/releases/2014/01/140110103522.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins